Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.58 |
| ▸ | SRC | P12931 | 3/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000628 | 0.85 | ABL1 (0.69) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL2941787 | 0.85 | ABL1 (0.75) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL27771353 | 0.84 | ABL1 (0.59) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL5465340 | 0.81 | ALDH1A1 (0.61) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL8353979 | 0.80 | CDK5 (0.58) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL4901211 | 0.79 | CDK5 (0.75) | ABL1SRCCDK5MEN1KMT2A | |
| SCHEMBL12801118 | 0.78 | CDK5 (0.73) | ABL1SRCCDK5MEN1KMT2A | |
| SCHEMBL4002108 | 0.75 | ABL1 (0.71) | ABL1SRCPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL5465964 | 0.74 | RAB9A (0.60) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL5472432 | 0.74 | RAB9A (0.65) | ABL1SRCPDGFRBPDGFRAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | ABL1 131/4885SRC 146/4885PDGFRB 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.